$261 Million is the total value of Aisling Capital Management LP's 13 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio (BBIO) | $134,442,000 | +63.3% | 3,835,722 | 0.0% | 51.51% | +20.0% | |
| EIDX | Eidos Therapeutics, Inc. (EIDIX) | $64,485,000 | +59.5% | 1,123,630 | 0.0% | 24.71% | +17.3% | |
| AVRO | AVROBIO, Inc. (AVRO) | $17,978,000 | +42.6% | 893,079 | 0.0% | 6.89% | +4.8% | |
| AGLE | Aeglea Biotherapeutics Inc (AGLE) | $9,864,000 | -0.7% | 1,291,151 | 0.0% | 3.78% | -27.0% | |
| BCEL | Atreca (BCEL) | $5,997,000 | +26.4% | 387,653 | 0.0% | 2.30% | -7.1% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $5,760,000 | -43.6% | 2,000,000 | 0.0% | 2.21% | -58.6% | |
| OBSV | ObsEva SA (OBSV) | $5,296,000 | -54.1% | 1,386,338 | 0.0% | 2.03% | -66.3% | |
| ZSAN | Buy | Zosano Pharma Corporation (ZSAN) | $4,132,000 | +30.6% | 2,718,226 | +34.0% | 1.58% | -4.1% |
| SNSS | Sunesis Pharmaceuticals, Inc. (SNSS) | $3,411,000 | -53.1% | 10,100,000 | 0.0% | 1.31% | -65.5% | |
| RCUS | Arcus Biosciences, Inc. (RCUS) | $3,367,000 | +11.0% | 333,333 | 0.0% | 1.29% | -18.4% | |
| VRNA | Verona Pharma plc (VRNA) | $2,551,000 | +25.9% | 443,596 | 0.0% | 0.98% | -7.6% | |
| Nabriva Therapeutics plc (NBRV) | $2,522,000 | -34.0% | 1,910,287 | 0.0% | 0.97% | -51.5% | ||
| ACRS | Aclaris Theraputics Inc (ACRS) | $1,199,000 | +75.0% | 634,455 | 0.0% | 0.46% | +28.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.